Stock MRVL MARVEL BIOSCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 07:04:32 26/06/2024 pm IST 		5-day change 1st Jan Change
0.115 CAD 0.00% Intraday chart for Marvel Biosciences Corp. +4.55% +43.75%
18/06 Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024 CI
16/05 Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in funding CI

Business Summary

Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.

Managers

Managers TitleAgeSince
Joseph Matheson CEO
 Chief Executive Officer - 14/21/14
Harry Nijjar DFI
 Director of Finance/CFO 36 01/22/01
Mark Williams PSD
 President 52 14/21/14
Jacqueline Groot SEC
 Corporate Secretary - -

Members of the board

Members of the board TitleAgeSince
S. Smallbone BRD
 Director/Board Member - 15/22/15
Joseph Matheson CEO
 Chief Executive Officer - 14/21/14
Mark Williams PSD
 President 52 14/21/14
Neil Allan Johnson BRD
 Director/Board Member 55 14/21/14
Babak Pedram BRD
 Director/Board Member 43 23/22/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 39,786,231 27,910,633 ( 70.15 %) 0 70.15 %

Shareholders

NameEquities%Valuation
Joseph Matheson
13.13 %
5,224,000 13.13 % 386 576 $
Mark Williams
12.57 %
5,000,049 12.57 % 370 004 $
Neil Allan Johnson
1.018 %
405,000 1.018 % 29 970 $
Babak Pedram
0.4989 %
198,500 0.4989 % 14 689 $

Company contact information

Marvel Biosciences Corp.

505 8th Avenue South West Suite 420

T2P 1G2, Calgary

+

http://www.marvelbiotechnology.com
address Marvel Biosciences Corp.(MRVL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MARVEL BIOSCIENCES CORP. Stock Marvel Biosciences Corp.
+43.75% 33.41L
MODERNA, INC. Stock Moderna, Inc.
+21.61% 4.69TCr
LONZA GROUP AG Stock Lonza Group AG
+37.63% 3.91TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.38% 3.85TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.33% 3.1TCr
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 2.61TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.31% 2.59TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+35.89% 1.25TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.52% 1.14TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.30% 1.06TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRVL Stock
  4. Company Marvel Biosciences Corp.